Dataset from A Phase III, Open, Randomized, Multicentric Study to Compare the Reactogenicity and Immunogenicity of GSK Biologicals' Combined Vi Polysaccharide Typhoid Vaccine and Inactivated Hepatitis A Vaccine, to That Elicited by GSK Biologicals' Hepatitis A Vaccine, Administered Singly or Concomitantly With GSK Biologicals' Vi Polysaccharide Vaccine

To evaluate the immunogenicity, reactogenicity and safety of Hepatyrix when compared to the concomitant administration of Typherix and Havrix, and when compared to the administration of monovalent vaccines, Havrix or Typhim Vi. Furthermore, the study will evaluate the persistence of anti-Vi and anti-HAV antibodies up to 36 months after administration of the first dose of the study vaccine.

本研究旨在评估Hepatyrix的免疫原性、反应原性与安全性，对照方案分为两类：一是Typherix与Havrix联合接种，二是单价疫苗Havrix或Typhim Vi单独接种。此外，本研究还将评估首剂接种研究疫苗后，抗Vi抗体与抗HAV抗体的持久性，最长随访时长可达接种后36个月。